

Central Committee on Research Involving Human Subjects/Minister of Health,  
Welfare and Sport  
PO Box 16302  
2500 BH The Hague

Groningen, 14 October 2019

**Subject: Digital submission of substantial amendment NL69548.056.19**

Dear members of the Central Committee on Research Involving Human Subjects/Minister of Health, Welfare and Sport,

With this letter I would like to ask the Competent Authority (Central Committee on Research Involving Human Subjects/Minister of Health, Welfare and Sport) to issue a certificate of no objection for a substantial amendment belonging to the research entitled "*A two-part parallel group study to assess the safety, tolerability and pharmacokinetic (PK) profile of multiple oral doses of RDN-929 in healthy older adults and subjects with early symptomatic Alzheimer's Disease*", registered under NL69548.056.19

The modification(s) of this amendment is/are concerning (*please tick where appropriate*):

- the addition of a new investigational medicinal product;
- a substantial modification of the current investigational medicinal product;
- otherwise, namely: With this amendment, the address of the sponsor was updated, the dosage level of Part 2 was set at 50 mg, the exclusion criterion regarding liver values at Screening was updated, the fasting requirement before clinical laboratory tests was updated, and a fasting requirement before PET scanning was added. Furthermore, sections describing stopping rules when liver values are increased 2x above ULN, describing additional one time hepatic assessments and describing study stopping rule were added.

With this submission I declare that all relevant documents from the above-mentioned research dossier are signed by the authorised people. The signed documents are/will be submitted for review to the responsible review committee specified in question 1 of the general assessment and registration form (ABR form).

Kind regards

5.1.2.e

**Enclosed documents**

A1 - Cover letter applicant CCMO, 14 October 2019

B3 - EudraCT application form CCMO, 14 October 2019

B5 - EudraCT Substantial Amendment Form CCMO, 14 October 2019